# TECH earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/TECH) · [Earnings tab](https://www.lopjlb.com/stock/TECH?tab=earnings)

Updated: 2026-08-12T05:35:26

Quarters analyzed: 8

## Cross-quarter narrative

Across eight quarterly calls Bio‑Techne’s operating picture shifted from modest organic growth and stable margins in late‑2024 to a mixed environment where biopharma demand stayed resilient while academic and emerging‑biotech spending weakened. Revenue growth moved from +1% (2024 Q4) to flat (2026 Q2) and a 2% decline in 2026 Q3, whereas adjusted operating margins trended upward, reaching 34.9% in 2025 Q3 before settling near 32%‑34% later. Management tone softened, reflecting heightened uncertainty around NIH funding, biotech financing and tariff proposals. China’s stimulus lag gave way to modest growth by 2026 Q3, but funding constraints persisted. The Wilson Wolf acquisition remained a multi‑year focus, shifting from on‑track to at‑risk before re‑stabilizing. AI‑designed proteins and the COMET spatial‑biology platform progressed from on‑track to delivery, underscoring a strategic pivot toward high‑value, technology‑driven products. Concurrently, the Exosome divestiture and capital reallocation signaled a sharpening on core growth pillars. Persistent policy and currency risks, together with emerging‑biotech softness, continued to temper outlook despite strong large‑pharma demand.

## Latest CallCard · Q3

Bio-Techne Q3 FY2026 showed a 2% organic revenue decline after timing headwinds, but delivered 34.2% operating margin, strong large‑pharma demand, China growth and AI initiatives, while biotech funding lag and emerging‑biotech softness keep outlook cautious.

**Guidance:** maintained — Management expects flat Q4 revenue, low single‑digit underlying growth and no change to prior outlook

**Tone:** mgmt 0.3 · Q&A pressure 0.6 · divergence 0.4

Prepared remarks emphasized sustained large‑pharma strength, improving academia and optimism on AI and future growth

### Demand visibility

Large pharma strong, U.S. academia stabilizing, China momentum, biotech uncertain

Sustained strength from large pharmaceutical customers and improving trends in U.S. academic market; China delivered fourth consecutive quarter of growth; emerging biotech spending remains soft pending funding lag

### Margins / costs

Operating margin improved sequentially, target 100bps Q4 expansion

Adjusted operating margin was 34.2% (up 310bps sequentially); margin expansion of ~100bps targeted for Q4 despite unfavorable mix; cost discipline and productivity initiatives cited

### Capital allocation

Focus on profitability, M&A and strategic investments

Generated $86.7m operating cash flow, returned $12.5m to shareholders, pursuing remainder of Wilson Wolf acquisition, prioritizing M&A, and investing in AI, cell‑therapy and spatial biology platforms

### Milestones

- **Wilson Wolf acquisition** [on_track]: 20% owned, on track to acquire remainder by end of calendar 2027
- **COMET Multiomic Spatial Platform** [delivered]: 65% growth and first system installed in China during quarter
- **Ella platform CE‑IVD marking** [delivered]: Enabled European clinical use of Ella immunoassay platform
- **AI collaboration with Providence Health & Microsoft** [on_track]: GigaTIME framework uses Bio‑Techne Spatial Biology data for 3‑D pathology
- **Strategic brand alignment to 3 brands** [delivered]: Reduced portfolio from 10 to 3 brands to simplify customer engagement
- **GMP protein revenue growth** [on_track]: Nearly 50% YoY growth when excluding fast‑track cell‑therapy customers
- **Spatial Biology backlog record** [on_track]: Record backlog for COMET platform positioning for continued growth
- **Cell‑therapy Fast Track designations** [new]: Two large customers received FDA Fast Track, accelerating timelines but reducing near‑term GMP demand

### Fears / risks

- **Biotech funding lag**: Funding improvements have not yet translated into spending, creating a 2‑3 quarter lag risk
- **Emerging biotech softness**: Revenue from emerging biotech declined high single digits, offsetting large‑pharma strength
- **OEM order timing**: Large OEM commercial supply order arrived early, creating a headwind to Q3 revenue
- **Customer concentration**: Diagnostics segment can be lumpy due to reliance on a few large customers
- **Interest rate exposure**: Net interest expense rose due to expiration of interest‑rate hedges
- **Currency impact**: Foreign exchange provided a 2% tailwind but adds volatility
- **Regulatory timing**: Fast Track designations reduce near‑term GMP reagent demand
- **Margin pressure from mix**: Unfavorable product mix and volume deleverage pressured margins

### Key quotes

> “Our quarterly performance was supported by sustained strength from our large pharmaceutical customers and stable to improving trends in our U.S. academic end market.”

> “Emerging biotech spending has yet to fully reflect improving funding conditions, engagement and activity levels with this customer base continue to trend positively.”

## Quarter one-liners

- **2026 Q3:** Bio-Techne Q3 FY2026 showed a 2% organic revenue decline after timing headwinds, but delivered 34.2% operating margin, strong large‑pharma demand, China growth and AI initiatives, while biotech funding lag and emerging‑biotech softness keep outlook cautious.
- **2026 Q2:** Bio-Techne posted flat Q2 revenue, expanded margins by ~100 bps, and highlighted confidence in its core portfolio amid mixed end‑market dynamics and ongoing acquisition of Wilson Wolf.
- **2026 Q1:** Organic revenue fell 1% as cell‑therapy timing and biotech funding softness weighed, but margin expanded 90bps to 29.9% and management stays upbeat on low‑single‑digit growth guidance.
- **2025 Q4:** Bio-Techne posted a solid Q4 with 3% organic revenue growth and 32% adjusted operating margin, while highlighting Exosome divestiture and noting ongoing NIH, tariff and biotech funding uncertainties that keep outlook at low single‑digit growth.
- **2025 Q3:** Bio‑Techne posted 6% organic Q3 growth, 34.9% operating margin, while noting NIH funding uncertainty, tariff risks and optimism around FDA‑driven organoid demand.
- **2025 Q2:** Bio‑Techne posted 9% revenue growth and a 30.1% operating margin, citing strong biopharma demand, AI‑designed proteins and new instrument launches while noting modest academic slowdown, FX headwinds and timing of large GMP orders.
- **2025 Q1:** Bio-Techne Q1 FY2025 showed 4% organic revenue growth, margin pressure from product mix, continued China headwinds, but progress on Wilson Wolf acquisition, AI‑designer proteins and COMET capacity expansion.
- **2024 Q4:** Bio-Techne reported Q4 FY2024 results in line with expectations, delivering 1% organic revenue growth and modest gains across its four growth verticals amid a challenging funding environment.

## Theme arcs

- **Revenue growth trajectory** (deteriorating): Organic growth fell from +1% in 2024 Q4 to flat in 2026 Q2 and a 2% decline in 2026 Q3
- **Margin performance** (improving): Margins expanded from ~30% in 2025 Q2 to mid‑30% range despite mix pressure
- **Biopharma demand** (stable): Large‑pharma demand remained strong throughout, supporting revenue despite other headwinds
- **Academic market demand** (deteriorating): NIH funding uncertainty and flat indirect‑cost rates created recurring academic slowdown
- **China market momentum** (improving): Initial stimulus lag in 2024 Q4 gave way to modest growth by 2026 Q3
- **Biotech funding environment** (deteriorating): Funding softness persisted, with >40% YoY decline in biotech financing noted in 2025 Q4

## Guidance path

2024 Q4:maintained → 2025 Q1:maintained → 2025 Q2:maintained → 2025 Q3:vague → 2025 Q4:maintained → 2026 Q1:maintained → 2026 Q2:maintained → 2026 Q3:maintained

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/TECH`